Table 3. Results of the stratified meta-analyses for trial eligibility criteria modifying DAS28-remission.
| Trial eligibility criteria | |||||
|---|---|---|---|---|---|
| VARIABLE: | Trials | OR (95% CI) | CE Rate | τ2 | p-interaction |
| Overall | 35 | 5.57 (4.24 to 7.3) | 0.026 | 0.32 | N.A. |
| DMARD History | 0.16 | 0.003 | |||
| DMARD-Naive | 5 | 2.93 (1.93 to 4.46) | 0.135 | ||
| DMARD-IR | 25 | 6.27 (4.71 to 8.34) | 0.026 | ||
| TT-IR | 5 | 10.30 (4.61 to 23.01) | 0.016 | ||
| csDMARD Handling at Randomisation | 0.29 | 0.34 | |||
| Naive | 0 | N.A. | N.A. | ||
| Not Using | 10 | 4.01 (2.45 to 6.55) | 0.015 | ||
| Continued | 8 | 6.73 (3.99 to 11.32) | 0.020 | ||
| Discontinued | 16 | 5.75 (3.85 to 8.59) | 0.028 | ||
| Not Reported | 1 | 13.42 (2.65 to 67.99) | 0.034 | ||
| MTX Handling at Randomisation | 0.18 | 0.007 | |||
| Naive | 4 | 2.87 (1.76 to 4.66) | 0.13 | ||
| Not Using | 2 | 4.43 (1.82 to 10.81) | 0.072 | ||
| Continued | 26 | 7.10 (5.31 to 9.50) | 0.018 | ||
| Discontinued | 3 | 2.86 (1.14 to 7.17) | 0.034 | ||
| Not Reported | 0 | N.A. | N.A. | ||
| TT Handling at Randomisation | 0.15 | 0.006 | |||
| Naive | 10 | 3.48 (2.46 to 4.94) | 0.072 | ||
| Not Using | 11 | 6.46 (4.14 to 10.06) | 0.016 | ||
| Continued | 0 | N.A. | N.A. | ||
| Discontinued | 11 | 8.95 (5.72 to 14.00) | 0.017 | ||
| Not Reported | 3 | 3.96 (2.04 to 7.71) | 0.028 | ||
| Max Disease Duration at Inclusion | 0.27 | 0.09 | |||
| Early Arthritis (≤2years) | 3 | 2.83 (1.48 to 5.40) | 0.147 | ||
| Not Reported | 28 | 6.19 (4.59 to 8.33) | 0.025 | ||
| Established Arthritis (>2 years) | 4 | 6.51 (2.69 to 15.78) | 0.008 | ||
| Min Required CRP at Inclusion | 0.23 | 0.04 | |||
| 4.5- 7mg/L or more | 9 | 3.15 (1.89 to 5.24) | 0.026 | ||
| 10 mg/L or more | 12 | 8.82 (5.79 to 13.44) | 0.028 | ||
| 15 mg/L or more | 9 | 5.04 (3.12 to 8.13) | 0.020 | ||
| 20 mg/L or more | 3 | 5.10 (2.19 to 11.86) | 0.021 | ||
| No Criteria Reported | 2 | 4.09 (1.63 to 10.25) | 0.074 | ||
| Serology | 0.30 | 0.17 | |||
| Mixed | 34 | 5.79 (4.40 to 7.62) | 0.025 | ||
| Only Seropositive | 1 | 2.41 (0.71 to 8.18) | 0.079 | ||
| Only Seronegative | 0 | N.A. | N.A. | ||
| Min Required 66 SJC at Inclusion | 0.38 | 0.95 | |||
| ≥3 | 0 | N.A. | N.A. | ||
| ≥4 | 5 | 6.13 (2.85 to 13.20) | 0.026 | ||
| ≥6 | 17 | 5.96 (3.95 to 9.00) | 0.021 | ||
| ≥8 | 3 | 4.66 (1.95 to 11.10) | 0.026 | ||
| ≥9 | 3 | 8.07 (2.07 to 31.46) | 0.008 | ||
| ≥10 | 7 | 4.95 (2.67 to 9.17) | 0.028 | ||
| Min Required 66 TJC at Inclusion | 0.39 | 0.91 | |||
| ≥4 | 5 | 6.14 (2.84 to 13.28) | 0.026 | ||
| ≥6 | 11 | 5.21 (2.96 to 9.15) | 0.017 | ||
| ≥8 | 8 | 6.87 (4.01 to 11.76) | 0.030 | ||
| ≥9 | 3 | 8.08 (2.07 to 31.63) | 0.008 | ||
| ≥10 | 2 | 4.08 (1.42 to 11.67) | 0.114 | ||
| ≥12 | 6 | 4.75 (2.44 to 9.26) | 0.028 | ||
CE, control event; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; csDMARD, conventional synthetic disease modifying antirheumatic drug; IR, inadequate responders; MTX, metothrexate; OR, odds ratio; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TT, Targeted therapy.